Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 13, 2023, Wheeler Bio, a contract development and manufacturing organization (CDMO), announced the closure of a $31 million Series A financing round, co-led by Charles River Laboratories (NYSE: CRL) and Echo. The funds will be used to complete a state-of-the-art CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with production expected to start in Q3 2023. Wheeler Bio's primary service, Portable CMC™, integrates development services to address client timelines and budgets, reducing risks associated with drug development. The company focuses on delivering small batch production for next-gen therapeutic proteins, positioning itself at the forefront of CMC drug development.
Charles River Laboratories International, Inc. (NYSE: CRL) will release its first-quarter 2023 financial results on May 11, before the market opens. A conference call to discuss the results is scheduled for 8:30 a.m. ET on the same day. Investors can listen to the live webcast through the Investor Relations section of the company's website, with a replay available afterward.
Charles River provides critical products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions worldwide. Their focus is on enhancing research and drug development processes to assist in the discovery and safe manufacture of new therapies.
Charles River Laboratories (NYSE: CRL) is showcasing its enhanced oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present 19 scientific posters and a spotlight presentation focusing on next-generation technologies in drug discovery and cell therapy development. Charles River has significantly contributed to cancer therapy advancements, being named co-inventors on 78 patents and supporting 16 clinical candidates, along with 11 FDA-approved therapies since 2018. Collaborative efforts with Cypre, Inc. and Kibur Medical are also highlighted, showcasing innovative approaches including the use of 3D hydrogel tumor models and implantable microdevices for enhanced drug-response tracking.
Charles River Laboratories (NYSE: CRL) will present at the Barclays Global Healthcare Conference on March 15 at 10:15 a.m. ET. The management will discuss the company's strategic focus and recent business developments. A live webcast of the presentation will be available on the Investor Relations website and will be archived for two weeks following the event. Charles River is dedicated to supporting pharmaceutical and biotechnology sectors by providing essential products and services that expedite research and drug development efforts. For more information, visit www.criver.com.
Charles River Laboratories International (NYSE: CRL) announces the launch of Apollo™, a secure cloud-based platform designed for drug developers. This platform streamlines access to study data, milestones, documents, and cost estimates, ultimately enhancing decision-making and client experience. Apollo is part of Charles River's digital strategy, fostering real-time data access and self-service tools for clients. Currently live for ongoing studies, Apollo aims to improve efficiency in preclinical studies.